((自动化翻译由路透提供，请见免责声明 ))
1月22日 -
** Disc Medicine 股价盘前下跌1.9%至59.35美元，生物制药公司寻求融资
* () * 总部位于马萨诸塞州沃特敦的公司于周二晚些时候开始发行2亿美元的股票，包括股票和预先筹资的认股权证。
** 该公司计划将募集资金净额用于候选产品的研究和临床开发，以支持其治疗红细胞生成性原卟啉症$(EPP.UK)$ 的潜在商业化。
红细胞生成性原卟啉症是一种罕见疾病，会导致患者对光敏感而疼痛。
** IRON收到美国FDA对的积极反馈 ()，随后IRON股价在周二上涨近4%，报收于60.52美元。
** 杰富瑞、Leerink、Stifel 和 Cantor 是此次股票发行的账簿管理人
** 截至周二，IRON 股价在 2025 年初下跌了 4.5%。该股 1 年最高价为 77.60 美元(3 月 4 日)，1 年最低价为 25.60 美元(4 月 1 日)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.